2025
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
Zhang J, Rajendran B, Desai S, Gibson J, DiPalermo J, LoRusso P, Kong Y, Zhao H, Cecchini M, Schalper K. High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties. Journal For ImmunoTherapy Of Cancer 2025, 13: e011653. PMID: 40935566, DOI: 10.1136/jitc-2025-011653.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesCD8+ tumor-infiltrating lymphocytesPromoter methylation statusMGMT expressionMGMT overexpressionClinical significanceAllogeneic peripheral blood mononuclear cellsCD8+ T cellsMGMT promoter methylation statusKilling of malignant cellsMGMT-expressing cellsMultiplexed quantitative immunofluorescencePeripheral blood mononuclear cellsAggressive clinical courseMGMT protein expressionAggressive colorectal cancerMethylation statusExpression of MGMTLevels of MGMT proteinMGMT protein levelsImmune evasion propertiesBlood mononuclear cellsMutational featuresAdaptive immune evasionSomatic mutation burden
2022
148 TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer
Ranjan K, Deen I, Rodas M, Gianino N, Ferrone S, Schalper K. 148 TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer. 2022, a161-a161. DOI: 10.1136/jitc-2022-sitc2022.0148.Peer-Reviewed Original Research
2016
Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
Datar I, Schalper KA. Epithelial–Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg? Clinical Cancer Research 2016, 22: 3422-3424. PMID: 27076625, PMCID: PMC4947415, DOI: 10.1158/1078-0432.ccr-16-0336.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply